Multiple Intravenous Administrations of Human Umbilical Cord Blood Cells Benefit in a Mouse Model of ALS


Autoria(s): Garbuzova-Davis, Svitlana; Rodrigues, Maria C. O.; Mirtyl, Santhia; Turner, Shanna; Mitha, Shazia; Sodhi, Jasmine; Suthakaran, Subatha; Eve, David J.; Sanberg, Cyndy D.; Kuzmin-Nichols, Nicole; Sanberg, Paul R.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

30/10/2013

30/10/2013

2012

Resumo

Background: A promising therapeutic strategy for amyotrophic lateral sclerosis (ALS) is the use of cell-based therapies that can protect motor neurons and thereby retard disease progression. We recently showed that a single large dose (25x10(6) cells) of mononuclear cells from human umbilical cord blood (MNC hUCB) administered intravenously to pre-symptomatic G93A SOD1 mice is optimal in delaying disease progression and increasing lifespan. However, this single high cell dose is impractical for clinical use. The aim of the present pre-clinical translation study was therefore to evaluate the effects of multiple low dose systemic injections of MNC hUCB cell into G93A SOD1 mice at different disease stages. Methodology/Principal Findings: Mice received weekly intravenous injections of MNC hUCB or media. Symptomatic mice received 10(6) or 2.5x10(6) cells from 13 weeks of age. A third, pre-symptomatic, group received 10(6) cells from 9 weeks of age. Control groups were media-injected G93A and mice carrying the normal hSOD1 gene. Motor function tests and various assays determined cell effects. Administered cell distribution, motor neuron counts, and glial cell densities were analyzed in mouse spinal cords. Results showed that mice receiving 10(6) cells pre-symptomatically or 2.5x10(6) cells symptomatically significantly delayed functional deterioration, increased lifespan and had higher motor neuron counts than media mice. Astrocytes and microglia were significantly reduced in all cell-treated groups. Conclusions/Significance: These results demonstrate that multiple injections of MNC hUCB cells, even beginning at the symptomatic disease stage, could benefit disease outcomes by protecting motor neurons from inflammatory effectors. This multiple cell infusion approach may promote future clinical studies.

Department of Neurosurgery and Brain Repair, at the University of South Florida (USF)

Department of Neurosurgery and Brain Repair, at the University of South Florida (USF)

Sao Paulo Research Foundation

Sao Paulo Research Foundation

Identificador

PLOS ONE, SAN FRANCISCO, v. 7, n. 2, supl. 1, Part 2, pp. 707-712, FEB 3, 2012

1932-6203

http://www.producao.usp.br/handle/BDPI/36767

10.1371/journal.pone.0031254

http://dx.doi.org/10.1371/journal.pone.0031254

Idioma(s)

eng

Publicador

PUBLIC LIBRARY SCIENCE

SAN FRANCISCO

Relação

PLOS ONE

Direitos

openAccess

Copyright PUBLIC LIBRARY SCIENCE

Palavras-Chave #AMYOTROPHIC-LATERAL-SCLEROSIS #HEMATOPOIETIC STEM-CELLS #MARROW STROMAL CELLS #ADULT BONE-MARROW #MOTOR-NEURON LOSS #DISEASE PROGRESSION #SPINAL-CORD #TRANSGENIC MICE #BRAIN REPAIR #FAMILIAL ALS #MULTIDISCIPLINARY SCIENCES
Tipo

article

original article

publishedVersion